Substance use disorder

Substance use disorder
source
Name	Substance use disorder
Field	Psychiatry, Addiction medicine

Substance use disorder is a clinical condition characterized by recurrent use of psychoactive substances leading to clinically significant impairment or distress. It spans a range of severity across legal and illegal substances and is addressed by clinical guidelines, public health agencies, and specialty organizations worldwide. Diagnostic criteria and management strategies have evolved through contributions from institutions and key figures in psychiatry and public health.

Definition and Classification

Clinical definitions derive from diagnostic manuals and classification systems created by institutions such as the American Psychiatric Association, World Health Organization, and national health ministries like the National Institutes of Health. The Diagnostic and Statistical Manual of Mental Disorders provides criteria used in clinical practice in countries influenced by United States psychiatry, while the International Classification of Diseases frames coding and epidemiology for the World Health Organization. Subtypes align with specific agents—examples include alcohol, opioid, stimulant, sedative-hypnotic, and cannabis. Classification systems inform coding by entities such as the Centers for Medicare & Medicaid Services and are referenced in guidance from professional bodies like the American Society of Addiction Medicine.

Signs and Symptoms

Clinical presentations often include behavioral patterns and physiological changes recognized by clinicians affiliated with institutions such as Mayo Clinic, Johns Hopkins Hospital, and university departments like Massachusetts General Hospital. Observable signs include impaired control over use, social impairment affecting workplaces like World Trade Center Health Program settings, risky use in contexts such as Interstate 95 travel or Trans-Siberian Railway migration routes, and pharmacological features like tolerance and withdrawal described in literature from researchers at Columbia University and University of Cambridge. Severe cases may involve complications managed by emergency services such as St Bartholomew's Hospital or trauma centers in cities like Los Angeles and New York City.

Causes and Risk Factors

Etiology is multifactorial: genetic predisposition studied at centers like Harvard Medical School and Stanford University interacts with environmental exposures documented in cohort studies from institutions such as Framingham Heart Study affiliates and longitudinal work by researchers at King's College London. Risk factors include early exposure in communities impacted by events like the Opioid epidemic in the United States and socioeconomic effects after incidents such as Hurricane Katrina or conflicts like the Syrian civil war. Co-occurring psychiatric disorders treated in clinics like Beth Israel Deaconess Medical Center and family histories described in registries such as those maintained by Kaiser Permanente increase vulnerability. Neurobiological mechanisms have been elucidated in laboratories at National Institute on Drug Abuse and through imaging consortia involving University College London.

Diagnosis and Screening

Diagnosis relies on structured interviews and screening tools developed and validated by research centers including World Health Organization, American Psychiatric Association, and universities such as Yale University and University of Toronto. Common instruments include clinician-administered assessments used in trials at National Institutes of Health and brief screens implemented in settings like clinics at Veterans Affairs hospitals. Laboratory testing and toxicology services provided by institutions like Quest Diagnostics or university hospitals augment clinical assessment. Diagnostic thresholds guide allocation of services under policies like those enacted by the Affordable Care Act and reimbursement rules from Centers for Medicare & Medicaid Services.

Treatment and Management

Evidence-based treatments combine pharmacotherapy, psychosocial interventions, and harm-reduction strategies developed by organizations such as the Substance Abuse and Mental Health Services Administration and implemented in programs run by Hazelden Betty Ford Foundation and hospital systems including Cleveland Clinic. Medications include opioid agonists and antagonists evaluated in trials at Food and Drug Administration-regulated centers and use protocols endorsed by the American Society of Addiction Medicine. Psychotherapies such as cognitive behavioral therapy and contingency management evolved in research at University of Pennsylvania and University of Vermont. Integrated care models link primary care settings like Mayo Clinic with specialty addiction services and community organizations including Red Cross affiliates during disaster responses.

Epidemiology and Impact

Epidemiological data are compiled by agencies such as World Health Organization, Centers for Disease Control and Prevention, and national statistical offices like the Office for National Statistics in the United Kingdom. Global and regional trends reflect patterns documented after events including the COVID-19 pandemic and policy shifts such as changes in regulation under laws like the Controlled Substances Act. Burden estimates inform reports produced by entities like the Global Burden of Disease consortium and are used by policymakers in parliaments and legislatures including the European Parliament and United States Congress to allocate resources.

Prevention and Harm Reduction

Prevention strategies are implemented through public health campaigns led by organizations such as the World Health Organization, Centers for Disease Control and Prevention, and charitable trusts exemplified by the Bill & Melinda Gates Foundation. Harm reduction services include needle and syringe programs, supervised consumption sites evaluated in trials in cities such as Vancouver, and distribution of naloxone supported by advocacy groups like the American Civil Liberties Union and public health departments in municipalities such as Chicago and San Francisco. School-based prevention curricula originate from research at universities like University of Michigan and community interventions coordinated with local entities such as YMCA branches.

Legal, Social, and Economic Aspects

Legal frameworks governing control, treatment, and criminalization differ across jurisdictions—from legislation such as the Controlled Substances Act to decriminalization initiatives in places like Portugal and regulatory approaches in countries including Canada and Australia. Social stigma and advocacy efforts involve nonprofits and professional associations such as National Alliance on Mental Illness and patient-led movements that have interacted with health systems like NHS England. Economic analyses by organizations including the World Bank and think tanks in cities like Washington, D.C. examine costs related to lost productivity, healthcare utilization in systems like Medicare, and criminal justice expenditures linked to policing and courts in metropolitan areas such as London and New York City.

Category:Addiction medicine